Voices
Raffaele Colombo: Subgroup Analysis of Prior EGFR and PD-1 Therapy
Raffaele Colombo/zymeworks.com

Raffaele Colombo: Subgroup Analysis of Prior EGFR and PD-1 Therapy

Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X:

“Subgroup analyses (caveat, small # of patients):

Prior anti-EGFR therapy:

  • yes = 15% ORR
  • no = 26% ORR

Prior PD-1 exposure:

  • 1st-line = 16% ORR
  • 2nd-line = 24% ORR

No correlation between responses and EGFR expression in this trial (authors’ data replotted by EGFR expression).”

Raffaele Colombo: Subgroup Analysis of Prior EGFR and PD-1 Therapy

More posts featuring Raffaele Colombo on OncoDaily.

cancer OncoDaily Oncology Raffaele Colombo